ABEO Share Price Performance
US$6.27
1.80 (40.27%)
Price US$6.27
Share PriceUS$6.27
ABEO Community Narratives
There are no narratives available yet.
Recent ABEO News & Updates
No updates
Abeona Therapeutics Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.86
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 46.6%
Abeona Therapeutics Inc. Competitors
About ABEO
- Founded
- 1974
- Employees
- 136
- CEO
- WebsiteView website
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
In the last week, the market has stayed flat, however the Consumer Staples sector stood out, gaining 3.2%. More promisingly, the market is up 20% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading